Related Experiment Video

Updated: Feb 17, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions

Smruthi Vijayaraghavan1, Stacy Moulder2, Khandan Keyomarsi3

  • 1Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, 6565 MD Anderson Blvd; Z6.2030, Houston, TX, 77030, USA.

Targeted Oncology
|December 9, 2017
PubMed

Insights

Cyclin-dependent kinase (CDK) inhibitors show promise in treating various cancers by controlling cell proliferation. CDK4/6 inhibitors are effective for breast cancer and are being explored for other malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cell cycle dysregulation drives uncontrolled cancer cell proliferation.
  • Cyclin-dependent kinases (CDKs) are key regulators of the cell cycle and are often implicated in cancer.
  • CDK inhibitors represent a targeted therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To review the clinical efficacy and ongoing research of CDK4/6 inhibitors (CDK4/6i) in cancer therapy.
  • To explore the potential of CDK4/6i in treating central nervous system malignancies and other cancer types.
  • To discuss the identification of biomarkers and resistance mechanisms for CDK4/6i.

Main Methods:

  • Review of clinical trial data for CDK4/6 inhibitors.
  • Analysis of pre-clinical research on CDK4/6i efficacy and resistance.
  • Evaluation of the blood-brain barrier penetration of certain CDK4/6i drugs.

Main Results:

  • CDK4/6 inhibitors are established as standard care for advanced hormone receptor-positive breast cancer.
  • CDK4/6i demonstrate safety and efficacy, with potential for treating central nervous system cancers.
  • Early-phase trials show promise for CDK4/6i in other breast cancer subtypes and non-breast malignancies.

Conclusions:

  • CDK4/6 inhibitors are a valuable therapeutic class for specific cancers, particularly breast cancer.
  • Further research is needed to optimize patient selection and combination therapies involving CDK4/6i.
  • Investigating biomarkers and resistance mechanisms will enhance the clinical application of CDK4/6i in broader oncological settings.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K